SCHEMBL13099548

SCHEMBL13099548

O=C(Nc1ccccc1)[C@H]1CC=C[C@H]2CCN(c3ccccc3)C(=O)[C@@H]12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HCRTR1 O43613 2/20 0.61
▸ OPRK1 P41145 2/20 0.52
▸ POLB P06746 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ FPR1 P21462 1/20 0.45
▸ FPR2 P25090 1/20 0.45
▸ ROCK2 O75116 1/20 0.43
▸ ROCK1 Q13464 1/20 0.43
▸ HDAC8 Q9BY41 2/20 0.41
▸ HDAC6 Q9UBN7 2/20 0.41
▸ HDAC1 Q13547 1/20 0.41
▸ ALDH1A1 P00352 3/20 0.40
▸ PREP P48147 2/20 0.40
▸ HTT P42858 2/20 0.40
▸ MAPT P10636 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13108437 1.00 HCRTR1 (0.61) HCRTR1OPRK1POLBTDP1MEN1
SCHEMBL13099584 0.92 HCRTR1 (0.54) HCRTR1OPRK1POLBTDP1MEN1
SCHEMBL13099597 0.92 HCRTR1 (0.58) HCRTR1OPRK1POLBTDP1MEN1
SCHEMBL13108448 0.92 HCRTR1 (0.58) HCRTR1OPRK1POLBTDP1MEN1
SCHEMBL13108384 0.92 HCRTR1 (0.54) HCRTR1OPRK1POLBTDP1MEN1
SCHEMBL13108593 0.91 HCRTR1 (0.52) HCRTR1OPRK1POLBFPR1FPR2
SCHEMBL13099551 0.91 HCRTR1 (0.52) HCRTR1OPRK1POLBFPR1FPR2
SCHEMBL13108668 0.88 OPRK1 (0.55) HCRTR1OPRK1MEN1KMT2AFPR1
SCHEMBL13397430 0.87 HCRTR1 (0.52) HCRTR1OPRK1POLBTDP1MEN1
SCHEMBL13099588 0.86 OPRK1 (0.57) HCRTR1OPRK1POLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140243333-A1 SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS UNIVERSITY OF KANSAS (US) 2014-08-28 — — US disclosed
US-20140243333-A1 SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS UNIVERSITY OF KANSAS (US) 2014-08-28 — — US disclosed
US-8735391-B2 Synthesis of functionalized octahydro-isoquinolin-1-one-8-carboxamides, octahydro-isoquinolin-1-one-8-carboxylic esters and analogs, and therapeutic methods UNIVERSITY OF KANSAS (US) 2014-05-27 — — US disclosed
US-8735391-B2 Synthesis of functionalized octahydro-isoquinolin-1-one-8-carboxamides, octahydro-isoquinolin-1-one-8-carboxylic esters and analogs, and therapeutic methods UNIVERSITY OF KANSAS (US) 2014-05-27 — — US disclosed
US-20100256142-A1 SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8- CARBOXAMIDES, OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS UNIVERSITY OF NORTH CAROLINA 2010-10-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256142-A1 SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8- CARBOXAMIDES, OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS OPRM1, OPRK1, OPRL1 HCRTR1 14/4885OPRK1 2/4885POLB 3739/4885
US-20140243333-A1 SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS OPRM1, OPRK1, OPRD1 HCRTR1 33/4885OPRK1 2/4885POLB 3979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback